"Acromegaly" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A condition caused by prolonged exposure to excessive HUMAN GROWTH HORMONE in adults. It is characterized by bony enlargement of the FACE; lower jaw (PROGNATHISM); hands; FEET; HEAD; and THORAX. The most common etiology is a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. (From Joynt, Clinical Neurology, 1992, Ch36, pp79-80)
| Descriptor ID |
D000172
|
| MeSH Number(s) |
C05.116.132.082 C10.228.140.617.738.250.100 C19.700.355.179
|
| Concept/Terms |
Acromegaly- Acromegaly
- Somatotropin Hypersecretion Syndrome (Acromegaly)
- Hypersecretion Syndrome, Somatotropin (Acromegaly)
- Hypersecretion Syndromes, Somatotropin (Acromegaly)
- Somatotropin Hypersecretion Syndromes (Acromegaly)
- Syndrome, Somatotropin Hypersecretion (Acromegaly)
- Syndromes, Somatotropin Hypersecretion (Acromegaly)
- Inappropriate GH Secretion Syndrome (Acromegaly)
- Inappropriate Growth Hormone Secretion Syndrome (Acromegaly)
|
Below are MeSH descriptors whose meaning is more general than "Acromegaly".
Below are MeSH descriptors whose meaning is more specific than "Acromegaly".
This graph shows the total number of publications written about "Acromegaly" by people in this website by year, and whether "Acromegaly" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2022 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Acromegaly" by people in Profiles.
-
Cardiovascular Disorders Associated With Acromegaly: an Update. Endocr Pract. 2024 Dec; 30(12):1212-1219.
-
Clinical Characteristics and Associated Factors of Colonic Polyps in Acromegaly. Exp Clin Endocrinol Diabetes. 2022 Nov; 130(11):714-722.
-
Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study. Acta Neuropathol Commun. 2016 06 01; 4(1):56.
-
X-linked acrogigantism syndrome: clinical profile and therapeutic responses. Endocr Relat Cancer. 2015 Jun; 22(3):353-67.
-
Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med. 2014 Dec 18; 371(25):2363-74.
-
Two birds with one stone: octreotide treatment for acromegaly and breast cancer. J Clin Oncol. 2013 Aug 10; 31(23):e398-400.
-
Inhibition of growth hormone receptor activation by pegvisomant may increase bone density in acromegaly. Horm Metab Res. 2011 Jan; 43(1):55-61.
-
Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. Eur J Endocrinol. 2008 Nov; 159(5):517-23.
-
Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab. 2005 Oct; 90(10):5684-91.
-
Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2005 Aug; 90(8):4465-73.